International consensus recommendations for management of New Onset Refractory Status Epilepticus (NORSE) incl. Febrile Infection-Related Epilepsy Syndrome (FIRES): Statements and Supporting Evidence.

Ronny Wickstrom, Olga Taraschenko, Robertino Dilena, Eric T Payne, Nicola Specchio, Rima Nabbout, Sookyong Koh, Nicolas Gaspard, Lawrence J Hirsch, International NORSE Consensus Group
Author Information
  1. Ronny Wickstrom: Neuropaediatric Unit, Department of Women´s and Children´s Health, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden.
  2. Olga Taraschenko: University of Nebraska Medical Center, Department of Neurological Sciences, Omaha, NE, USA.
  3. Robertino Dilena: Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neuropathophysiology Unit, Milan, Italy.
  4. Eric T Payne: Alberta Children's Hospital, Department of Pediatrics, Section of Neurology. Calgary, Canada.
  5. Nicola Specchio: Rare and Complex Epilepsy Unit, Department of Neurosciences, Bambino Gesù Children's Hospital, IRCCS, Rome, Full Member of European Reference Network EpiCARE, Italy.
  6. Rima Nabbout: Centre de reference epilepsies rares, department of pediatric Neurology, APHP, member of EPICARE ERN, Universite de Paris, Institut Imagine, INSERM 1163, Paris, France.
  7. Sookyong Koh: Children's Hospital and Medical Center, Department of Pediatrics, University of Nebraska, Omaha, NE, USA.
  8. Nicolas Gaspard: Université Libre de Bruxelles, Hôpital Erasme, Brussels, Belgium.
  9. Lawrence J Hirsch: Comprehensive Epilepsy Center, Department of Neurology, Yale University, New Haven, CT, USA.

Abstract

OBJECTIVE: To develop consensus-based recommendations for the management of adult and paediatric patients with NORSE/FIRES based on best evidence and experience.
METHODS: The Delphi methodology was followed. A facilitator group of 9 experts was established, who defined the scope, users and suggestions for recommendations. Following a review of the current literature, recommendation statements concerning diagnosis, treatment and research directions were generated which were then voted on a scale of 1 (strongly disagree) to 9 (strongly agree) by a panel of 48 experts in the field. Consensus that a statement was appropriate was reached if the median score was greater or equal to 7, and inappropriate if the median score was less than or equal to 3. The analysis of evidence was mapped to the results of each statement included in the Delphi survey.
RESULTS: Overall, 85 recommendation statements achieved consensus. The recommendations are divided into five sections: 1) disease characteristics, 2) diagnostic testing and sampling, 3) acute treatment, 4) treatment in the post-acute phase, and 5) research, registries and future directions in NORSE/FIRES. The detailed results and discussion of all 85 statements are outlined herein. A corresponding summary of findings and practical flowsheets are presented in a companion article.
SIGNIFICANCE: This detailed analysis offers insight into the supporting evidence and the current gaps in the literature that are associated with expert consensus statements related to NORSE/FIRES. The recommendations generated by this consensus can be used as a guide for the diagnosis, evaluation, and management of patients with NORSE/FIRES, and for planning of future research.

Keywords

References

  1. Epilepsia. 2010 Jul;51(7):1323-8 [PMID: 20345937]
  2. Biomed J. 2020 Jun;43(3):205-210 [PMID: 32330681]
  3. Neurology. 2014 Feb 25;82(8):665-70 [PMID: 24453083]
  4. Epileptic Disord. 2020 Dec 1;22(6):811-816 [PMID: 33331273]
  5. J Neurol. 2011 Feb;258(2):218-22 [PMID: 20803213]
  6. Int J Mol Sci. 2021 Jun 11;22(12): [PMID: 34208064]
  7. Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):921-931 [PMID: 34462791]
  8. Epilepsia. 2001 Nov;42(11):1461-7 [PMID: 11879350]
  9. Epilepsia. 2018 Oct;59 Suppl 2:100-107 [PMID: 30159876]
  10. J Neurol Neurosurg Psychiatry. 2015 Jul;86(7):820-2 [PMID: 25398790]
  11. Ann Neurol. 2018 Dec;84(6):940-945 [PMID: 30408233]
  12. Epilepsia. 2011 Nov;52(11):e185-9 [PMID: 22004046]
  13. Pediatr Crit Care Med. 2020 Jan;21(1):59-66 [PMID: 31568262]
  14. Epilepsia Open. 2021 Sep;6(3):539-547 [PMID: 34098587]
  15. Epilepsy Behav. 2015 Jun;47:17-23 [PMID: 26010959]
  16. Eur J Neurol. 2011 Jan;18(1):19-e3 [PMID: 20880069]
  17. Epileptic Disord. 2017 Mar 1;19(1):99-103 [PMID: 28287071]
  18. Ann Neurol. 2019 Apr;85(4):526-537 [PMID: 30779222]
  19. Epilepsia. 2021 Jul;62(7):1629-1642 [PMID: 34091885]
  20. Dev Med Child Neurol. 2020 Aug;62(8):897-905 [PMID: 32372459]
  21. Curr Neurol Neurosci Rep. 2015 Mar;15(3):3 [PMID: 25637289]
  22. Neurol Neuroimmunol Neuroinflamm. 2017 Sep 25;4(6):e396 [PMID: 28959704]
  23. Neurology. 2014 Feb 25;82(8):656-64 [PMID: 24319039]
  24. Epilepsy Res. 2012 Nov;102(1-2):109-12 [PMID: 22591750]
  25. Neuropediatrics. 2017 Feb;48(1):5-18 [PMID: 27919115]
  26. Seizure. 2017 Apr;47:1-4 [PMID: 28267658]
  27. Ann Clin Transl Neurol. 2020 Aug;7(8):1429-1435 [PMID: 32666661]
  28. Neurol Neuroimmunol Neuroinflamm. 2020 Jul 29;7(5): [PMID: 32727813]
  29. Childs Nerv Syst. 2022 Jul;38(7):1401-1404 [PMID: 34762158]
  30. Brain Dev. 2010 Jan;32(1):51-6 [PMID: 19850427]
  31. Biomed J. 2020 Jun;43(3):293-304 [PMID: 32651134]
  32. Neurol Neuroimmunol Neuroinflamm. 2017 May 10;4(4):e353 [PMID: 28680914]
  33. Child Neurol Open. 2020 Dec 15;7:2329048X20979253 [PMID: 33403221]
  34. Epilepsy Curr. 2016 Jan-Feb;16(1):48-61 [PMID: 26900382]
  35. Epilepsia. 2018 Sep;59(9):1753-1763 [PMID: 30132834]
  36. Epilepsia. 2019 Apr;60(4):585-592 [PMID: 30854647]
  37. J Neurol Sci. 2016 Sep 15;368:272-6 [PMID: 27538648]
  38. Dev Med Child Neurol. 2018 Aug;60(8):765-779 [PMID: 29856068]
  39. WMJ. 2019 Oct;118(3):135-139 [PMID: 31682750]
  40. Seizure. 2020 Feb;75:174-184 [PMID: 31757748]
  41. Brain. 2014 May;137(Pt 5):1429-38 [PMID: 24595203]
  42. Epilepsy Behav Case Rep. 2017 Aug 19;8:100-104 [PMID: 29062691]
  43. Biomed J. 2020 Jun;43(3):277-284 [PMID: 32330677]
  44. J Neuroinflammation. 2018 Feb 09;15(1):38 [PMID: 29426321]
  45. Epilepsia. 2012 Jan;53(1):101-10 [PMID: 22191582]
  46. Epilepsia. 2010 Oct;51(10):2033-7 [PMID: 20813015]
  47. Epilepsia. 2017 Jun;58(6):973-982 [PMID: 28470748]
  48. Seizure. 2018 Jul;59:72-76 [PMID: 29754014]
  49. J Clin Neurophysiol. 2021 Nov 1;38(6):494-502 [PMID: 34261110]
  50. J Child Neurol. 2018 Sep;33(10):651-658 [PMID: 29877124]
  51. Acta Neurol Scand. 2010 Apr;121(4):251-6 [PMID: 20028339]
  52. Seizure. 2013 Jan;22(1):70-3 [PMID: 23068971]
  53. Eur J Neurol. 2022 Feb;29(2):626-647 [PMID: 34661330]
  54. Brain Sci. 2021 Sep 08;11(9): [PMID: 34573203]
  55. Hum Vaccin Immunother. 2015;11(8):2021-9 [PMID: 26260962]
  56. Ann Clin Transl Neurol. 2020 Dec;7(12):2467-2474 [PMID: 33506622]
  57. Brain Dev. 2012 Oct;34(9):763-7 [PMID: 22265641]
  58. Epilepsy Res. 2006 Apr;69(1):67-79 [PMID: 16469483]
  59. Pediatr Neurol. 2012 Dec;47(6):448-50 [PMID: 23127267]
  60. Congenit Heart Dis. 2017 Sep;12(5):641-643 [PMID: 28580631]
  61. Epilepsia. 2018 Apr;59(4):745-752 [PMID: 29476535]
  62. Seizure. 2020 Jan;74:41-48 [PMID: 31830676]
  63. Seizure. 2017 Mar;46:24-30 [PMID: 28222319]
  64. Int Immunol. 2022 Jan 22;34(2):107-118 [PMID: 34498051]
  65. Seizure. 2018 Feb;55:66-69 [PMID: 29414137]
  66. Brain Dev. 2016 Sep;38(8):772-6 [PMID: 26906012]
  67. Epilepsia. 2011 Nov;52(11):1956-65 [PMID: 21883180]
  68. Curr Neurol Neurosci Rep. 2002 Nov;2(6):534-40 [PMID: 12359109]
  69. Seizure. 2016 Feb;35:80-2 [PMID: 26803054]
  70. Neuropediatrics. 2012 Aug;43(4):209-16 [PMID: 22911482]
  71. J Child Neurol. 2017 Jan;32(1):35-40 [PMID: 27655472]
  72. Drugs. 2015 Sep;75(13):1499-521 [PMID: 26310189]
  73. Neurology. 2015 Oct 6;85(14):1224-32 [PMID: 26341869]
  74. Dev Med Child Neurol. 2019 May;61(5):540-546 [PMID: 30659589]
  75. Epilepsia. 2017 Jun;58(6):1102-1111 [PMID: 28448686]
  76. Neurology. 2016 Jan 19;86(3):253-60 [PMID: 26701381]
  77. Neurocrit Care. 2013 Aug;19(1):4-9 [PMID: 23589183]
  78. Epilepsia. 2019 Aug;60(8):1678-1688 [PMID: 31283843]
  79. Epilepsia. 2018 Apr;59(4):739-744 [PMID: 29399791]
  80. Epilepsy Behav. 2019 Dec;101(Pt B):106298 [PMID: 31133509]
  81. EMBO Mol Med. 2015 Nov 26;7(12):1503-12 [PMID: 26612854]
  82. Neurocrit Care. 2012 Aug;17(1):3-23 [PMID: 22528274]
  83. Epilepsy Behav. 2019 Jun;95:117-123 [PMID: 31035103]
  84. Neurology. 2020 Oct 20;95(16):e2280-e2285 [PMID: 32943479]
  85. Eur J Paediatr Neurol. 2019 Sep;23(5):749-754 [PMID: 31446001]
  86. Neurocrit Care. 2013 Apr;18(2):193-200 [PMID: 23097138]
  87. Case Rep Neurol Med. 2019 Jan 21;2019:7852017 [PMID: 30805233]
  88. Nat Rev Genet. 2019 Jun;20(6):341-355 [PMID: 30918369]
  89. Epilepsia. 2011 Oct;52 Suppl 8:28-30 [PMID: 21967356]
  90. Eur J Radiol. 2013 Nov;82(11):1964-72 [PMID: 23787273]
  91. Epilepsia. 2022 Aug 23;: [PMID: 35997591]
  92. JAMA Netw Open. 2019 Oct 2;2(10):e1914274 [PMID: 31664448]
  93. Epilepsy Res. 2010 Oct;91(2-3):143-52 [PMID: 20675100]
  94. Epilepsia. 2012 Jul;53(7):1276 [PMID: 22759241]
  95. Seizure. 2019 May;68:72-78 [PMID: 30482654]
  96. Epilepsia Open. 2020 Apr 14;5(2):307-313 [PMID: 32524057]
  97. Neurology. 2019 Apr 23;92(17):802-810 [PMID: 30894443]
  98. Pediatrics. 2014 Nov;134(5):e1431-5 [PMID: 25332495]
  99. Seizure. 2013 Sep;22(7):553-9 [PMID: 23643626]
  100. J Clin Neurophysiol. 2015 Apr;32(2):87-95 [PMID: 25626778]
  101. Epilepsia. 2016 Jan;57(1):e7-e11 [PMID: 26592968]
  102. Pharmacol Rev. 2020 Jul;72(3):606-638 [PMID: 32540959]
  103. Sleep Med Clin. 2016 Mar;11(1):25-38 [PMID: 26972031]
  104. Neurocrit Care. 2013 Apr;18(2):216-27 [PMID: 23065689]
  105. Neurology. 2011 Aug 9;77(6):589-93 [PMID: 21795662]
  106. Epilepsy Res. 2015 May;112:100-13 [PMID: 25847345]
  107. Lancet Neurol. 2011 Jan;10(1):99-108 [PMID: 21163447]
  108. J Clin Neurosci. 2020 Dec;82(Pt B):247-248 [PMID: 33246907]
  109. Brain Stimul. 2019 Sep - Oct;12(5):1101-1110 [PMID: 31126871]
  110. Epilepsia Open. 2019 Mar 27;4(2):344-350 [PMID: 31168503]
  111. Lancet Neurol. 2008 Dec;7(12):1091-8 [PMID: 18851928]
  112. Neurology. 2015 Nov 3;85(18):1604-13 [PMID: 26296517]
  113. J Neurol Sci. 2009 Feb 15;277(1-2):26-31 [PMID: 19013586]
  114. Epilepsy Res Treat. 2012;2012:209701 [PMID: 22953058]
  115. Epilepsia. 2007 Apr;48(4):732-42 [PMID: 17319915]
  116. Seizure. 2020 Jul;79:61-68 [PMID: 32417686]
  117. J Neurol. 2016 Apr;263(4):799-806 [PMID: 26914931]
  118. Ann Neurol. 2016 Dec;80(6):939-945 [PMID: 27770579]
  119. Epilepsia. 2021 Feb;62(2):303-324 [PMID: 33316111]
  120. Pediatr Neurol. 2018 Mar;80:61-69 [PMID: 29373157]

Grants

  1. P20 GM130447/NIGMS NIH HHS
  2. UL1 TR001863/NCATS NIH HHS

Word Cloud

Created with Highcharts 10.0.0recommendationsNORSE/FIRESstatementsconsensusmanagementevidenceDelphitreatmentresearchpatients9expertscurrentliteraturerecommendationdiagnosisdirectionsgenerated1stronglystatementmedianscoreequal3analysisresults85futuredetailedRefractoryStatusEpilepsyepilepticusOBJECTIVE:developconsensus-basedadultpaediatricbasedbestexperienceMETHODS:methodologyfollowedfacilitatorgroupestablisheddefinedscopeuserssuggestionsFollowingreviewconcerningvotedscaledisagreeagreepanel48fieldConsensusappropriatereachedgreater7inappropriatelessmappedincludedsurveyRESULTS:Overallachieveddividedfivesections:diseasecharacteristics2diagnostictestingsamplingacute4post-acutephase5registriesdiscussionoutlinedhereincorrespondingsummaryfindingspracticalflowsheetspresentedcompanionarticleSIGNIFICANCE:offersinsightsupportinggapsassociatedexpertrelatedcanusedguideevaluationplanningInternationalNewOnsetEpilepticusNORSEinclFebrileInfection-RelatedSyndromeFIRES:StatementsSupportingEvidenceAdultAnti-seizuremedicationImmunotherapyKetogenicdietPediatricstatus

Similar Articles

Cited By